WEKO3
アイテム
{"_buckets": {"deposit": "d2ed828a-c97e-42a5-a842-da3f88500a7d"}, "_deposit": {"created_by": 6, "id": "26363", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "26363"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00026363", "sets": ["11"]}, "author_link": ["117496", "117495", "117493", "117494", "117500", "117498", "117497", "117499"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-02-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "254", "bibliographicPageStart": "244", "bibliographicVolumeNumber": "24", "bibliographic_titles": [{"bibliographic_title": "Journal of Medical Economics"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aims: Estimating the monetary value of the convenience of using influenza antivirals approved in Japan from a patient perspective using a conjoint analysis. Methods: An online survey (August 2020) was performed on individuals aged 20–64 years living in Japan who had taken oral or inhalant antivirals for influenza treatment in the 2018/19 or 2019/20 seasons. Efficacy and safety were assumed to be equivalent among the antivirals. The attributes for the conjoint analysis included route (oral or inhalant), duration, frequency of administration, and out-ofpocket expenses. A conditional logit model was applied as a baseline model. The monetary value of each attribute was calculated by comparing the same utility of the linearly interpolated level of the out-of-pocket attribute. Another survey to determine the experiences of the latest antiviral intake was also conducted on the same respondents. Results: Of the respondents, 1,550 were men and 1,587 were women. The monetary value for oral antivirals was estimated to be higher, saving JPY 741 (USD 7.06, as of August 2020), compared with inhalant. Regarding the length and frequency of administration, five days corresponds to an increase of JPY 2,072, compared with one day, and twice a day corresponds to a JPY 574 increase compared to once a day. Conclusions: The results suggest that – among the antivirals approved in Japan – the monetary value of the utility is the highest in the single dose oral antiviral, baloxavir marboxil (baloxavir). Although the drug cost was highest in baloxavir among the brand antivirals, the difference in the value of utility for influenza patient was estimated to be larger than the difference in the drug costs. Limitations: Although individuals with diverse attributes from all over the country were included in the survey, they are not necessarily a representative population of the Japanese society.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Journal of Medical Economics, 24(1), pp.244-254; 2021", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Taylor and Francis Ltd."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1080/13696998.2021.1877150", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor \u0026 Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1369-6998", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hosogaya, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "117493", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takazono, Takahiro"}], "nameIdentifiers": [{"nameIdentifier": "117494", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yokomasu, Akira"}], "nameIdentifiers": [{"nameIdentifier": "117495", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroi, Shinzo"}], "nameIdentifiers": [{"nameIdentifier": "117496", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeoka, Hidetoshi"}], "nameIdentifiers": [{"nameIdentifier": "117497", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iwasaki, Kosuke"}], "nameIdentifiers": [{"nameIdentifier": "117498", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takeshima, Tomomi"}], "nameIdentifiers": [{"nameIdentifier": "117499", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mukae, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "117500", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-03-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JME24_244.pdf", "filesize": [{"value": "2.4 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2400000.0, "url": {"label": "JME24_244.pdf ", "url": "https://nagasaki-u.repo.nii.ac.jp/record/26363/files/JME24_244.pdf"}, "version_id": "95b13510-d564-4281-b46c-2f84c58dee86"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Antivirals", "subitem_subject_scheme": "Other"}, {"subitem_subject": "baloxavir", "subitem_subject_scheme": "Other"}, {"subitem_subject": "conjoint analysis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "dosage forms", "subitem_subject_scheme": "Other"}, {"subitem_subject": "influenzainhalation administration", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neuraminidase inhibitors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "on line survey", "subitem_subject_scheme": "Other"}, {"subitem_subject": "oral administrations", "subitem_subject_scheme": "Other"}, {"subitem_subject": "patient preference", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis"}]}, "item_type_id": "2", "owner": "6", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/00040559", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-03-22"}, "publish_date": "2021-03-22", "publish_status": "0", "recid": "26363", "relation": {}, "relation_version_is_last": true, "title": ["Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis"], "weko_shared_id": -1}
Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis
http://hdl.handle.net/10069/00040559
http://hdl.handle.net/10069/00040559a8a913ec-c19b-4139-bfce-c552ff0656bd
名前 / ファイル | ライセンス | アクション |
---|---|---|
JME24_244.pdf (2.4 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-03-22 | |||||
タイトル | ||||||
タイトル | Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Antivirals | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | baloxavir | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | conjoint analysis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | dosage forms | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | influenzainhalation administration | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | neuraminidase inhibitors | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | on line survey | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | oral administrations | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | patient preference | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Hosogaya, Naoki
× Hosogaya, Naoki× Takazono, Takahiro× Yokomasu, Akira× Hiroi, Shinzo× Ikeoka, Hidetoshi× Iwasaki, Kosuke× Takeshima, Tomomi× Mukae, Hiroshi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aims: Estimating the monetary value of the convenience of using influenza antivirals approved in Japan from a patient perspective using a conjoint analysis. Methods: An online survey (August 2020) was performed on individuals aged 20–64 years living in Japan who had taken oral or inhalant antivirals for influenza treatment in the 2018/19 or 2019/20 seasons. Efficacy and safety were assumed to be equivalent among the antivirals. The attributes for the conjoint analysis included route (oral or inhalant), duration, frequency of administration, and out-ofpocket expenses. A conditional logit model was applied as a baseline model. The monetary value of each attribute was calculated by comparing the same utility of the linearly interpolated level of the out-of-pocket attribute. Another survey to determine the experiences of the latest antiviral intake was also conducted on the same respondents. Results: Of the respondents, 1,550 were men and 1,587 were women. The monetary value for oral antivirals was estimated to be higher, saving JPY 741 (USD 7.06, as of August 2020), compared with inhalant. Regarding the length and frequency of administration, five days corresponds to an increase of JPY 2,072, compared with one day, and twice a day corresponds to a JPY 574 increase compared to once a day. Conclusions: The results suggest that – among the antivirals approved in Japan – the monetary value of the utility is the highest in the single dose oral antiviral, baloxavir marboxil (baloxavir). Although the drug cost was highest in baloxavir among the brand antivirals, the difference in the value of utility for influenza patient was estimated to be larger than the difference in the drug costs. Limitations: Although individuals with diverse attributes from all over the country were included in the survey, they are not necessarily a representative population of the Japanese society. | |||||
書誌情報 |
Journal of Medical Economics 巻 24, 号 1, p. 244-254, 発行日 2021-02-12 |
|||||
出版者 | ||||||
出版者 | Taylor and Francis Ltd. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1369-6998 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1080/13696998.2021.1877150 | |||||
権利 | ||||||
権利情報 | © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal of Medical Economics, 24(1), pp.244-254; 2021 |